Brand/Generic Battles Over REMS Raise Constitutional Questions For FDA
Executive Summary
ANDA sponsors may increasingly face a new roadblock to FDA approval: a Risk Evaluation and Mitigation Strategy (REMS) that restricts access to samples of the brand name product.
You may also be interested in...
Brand, Generic Disputes Over Access Move Beyond REMS Restrictions
Generic companies say innovators are using voluntary restricted distribution programs to prevent them from obtaining reference drugs for bioequivalence testing; a July hearing is set in a dispute involving Actelion’s Gaucher disease drug Zavesca, which is not subject to a Risk Evaluation and Mitigation Strategy.
Playing It Too Safe?: FTC Investigating Use Of REMS To Block Generics
The Federal Trade Commission is looking into whether companies are using their Risk Evaluation and Mitigation Strategies to thwart generic competition.
Generics Should Get REMS Exemption For Sample Collection, GPhA Says
FDA should create a system to allow generic firms that want to develop ANDAs for products in closed distribution systems to obtain samples from the brand sponsors, the Generic Pharmaceutical Association says